These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19660136)

  • 1. Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
    Malavasi N; Ponti G; Depenni R; Bertolini F; Zironi S; Luppi G; Conte PF
    J Hematol Oncol; 2009 Aug; 2():35. PubMed ID: 19660136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful combination therapy of radical liver resection with 5-fluorouracil/leucovorin, oxaliplatin, plus bevacizumab for ascending colon cancer with pulmonary and 43 liver metastases: report of a case.
    Ochiai T; Masuda T; Yagi M; Kasai R; Furuyama T; Tsukamoto K; Ito H; Igari K; Aihara A; Kumagai Y; Iida M; Odajima H; Tanaka S; Arii S; Yamazaki S
    Int Surg; 2012; 97(1):6-13. PubMed ID: 23101994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver resection after FOLFOX with bevacizumab.
    Mickle M; Mulcahy MF
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):12-4. PubMed ID: 17491587
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab].
    Inoue M; Uehara K; Ishiguro S; Nishio H; Ebata T; Yokoyama Y; Kokuryo T; Tsunoda N; Igami T; Sugawara G; Fukaya M; Nagino M
    Nihon Shokakibyo Gakkai Zasshi; 2010 May; 107(5):760-7. PubMed ID: 20460850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
    Leite D; Kater FR
    Anticancer Drugs; 2011 Jun; 22 Suppl 2():S1-7. PubMed ID: 21768791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
    Naiken SP; Toso C; Rubbia-Brandt L; Thomopoulos T; Roth A; Mentha G; Morel P; Gervaz P
    BMC Surg; 2014 Jan; 14():4. PubMed ID: 24438090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
    Jakab F
    Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases.
    Kishi Y; Zorzi D; Contreras CM; Maru DM; Kopetz S; Ribero D; Motta M; Ravarino N; Risio M; Curley SA; Abdalla EK; Capussotti L; Vauthey JN
    Ann Surg Oncol; 2010 Nov; 17(11):2870-6. PubMed ID: 20567921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy].
    Otsuka S; Inagaki M; Nishie M; Hamano R; Tokunaga N; Takahashi K; Tsunemitsu Y; Miyoshi K; Iwakawa K; Takahashi M; Iwagak H
    Gan To Kagaku Ryoho; 2009 Nov; 36(12):2166-8. PubMed ID: 20037358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX.
    Klinger M; Tamandl D; Eipeldauer S; Hacker S; Herberger B; Kaczirek K; Dorfmeister M; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2010 Aug; 17(8):2059-65. PubMed ID: 20177795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG).
    Huiskens J; van Gulik TM; van Lienden KP; Engelbrecht MR; Meijer GA; van Grieken NC; Schriek J; Keijser A; Mol L; Molenaar IQ; Verhoef C; de Jong KP; Dejong KH; Kazemier G; Ruers TM; de Wilt JH; van Tinteren H; Punt CJ
    BMC Cancer; 2015 May; 15():365. PubMed ID: 25943574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Partial response after transcatheter arterial infusion chemotherapy in a patient with systemic chemotherapy-resistant unresectable colon cancer and hepatic metastasis: (case report).
    Sawai K; Goi T; Koneri K; Katayama K; Yamaguchi A
    World J Surg Oncol; 2013 Aug; 11(1):203. PubMed ID: 23957924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
    Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
    Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of ascending colon cancer with unresectable distant metastases treated by systemic chemotherapy].
    Sugimoto K; Tashiro Y; Nagayasu K; Niwa K; Ono S; Ishiyama S; Hata M; Komiyama H; Takahashi M; Yaginuma Y; Kojima Y; Goto M; Tanaka M; Sengoku H; Okuzawa A; Tomiki Y; Sakamoto K
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1167-70. PubMed ID: 20567130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
    Liang JT; Lai HS; Cheng KW
    Surg Endosc; 2011 Jan; 25(1):305-8. PubMed ID: 20526625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy.
    Funaioli C; Pinto C; Di Fabio F; Santini D; Ceccarelli C; De Raffaele E; Fanti S; Castellucci P; Longobardi C; Buggi F; Martoni AA
    Tumori; 2007; 93(6):611-5. PubMed ID: 18338499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer.
    Bertolini F; Malavasi N; Scarabelli L; Fiocchi F; Bagni B; Del Giovane C; Colucci G; Gerunda GE; Depenni R; Zironi S; Fontana A; Pettorelli E; Luppi G; Conte PF
    Br J Cancer; 2011 Mar; 104(7):1079-84. PubMed ID: 21386839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.